Magnus Financial Group reduced its Johnson & Johnson holdings by 9.9% in Q4, selling 2,124 shares. Meanwhile, insiders sold over 30,000 shares recently. Despite this, J&J received FDA approval for a new immunology drug, Icotyde, boosting growth prospects. Analysts remain mostly positive, with price targets raised amid cautious market sentiment. The company also declared a quarterly dividend of $1.30 per share, maintaining steady income for investors.
Johnson & Johnson reported strong Q2 earnings, driven by a 41.1% year-on-year sales increase of its depression treatment Spravato, reaching $584 million. The company raised its 2026 adjusted diluted EPS guidance from $11.45-$11.65 to $11.6-$11.75, re...
Johnson & Johnson reported strong Q2 sales of $584 million for Spravato, a nasal spray for treatment-resistant depression, signaling robust market potential for psychedelic drugs. Jefferies highlights this growth supports the commercial viability of ...
Johnson & Johnson reported solid Q2 2026 results, achieving 6.6% annual revenue growth driven by strong Pharma and MedTech divisions. The company maintains a portfolio of over 15 blockbuster drugs and a promising pipeline, supporting its status as a ...
Johnson & Johnson reported better-than-expected Q2 2026 results with adjusted EPS of $2.90, surpassing estimates, and revenue of $25.31 billion, driven by strong pharmaceutical sales. Key growth came from the Innovative Medicine segment, with notable...
The FTSE 100 dropped 23 points to 10,506, pressured by mining stocks reacting to China's slower-than-expected 4.3% GDP growth in Q2, its weakest in three years. European markets also declined, while US futures rose, led by tech. PayPal shares surged ...
